Navigation Links
3SBio Inc. Announces Preliminary Third Quarter 2008 Results
Date:10/31/2008

-- Expects One-Time Impairment Charge of RMB19.0 million (US$2.7 million)

-- Affirms 2008 Full Year Guidance

SHENYANG, China, Oct. 31 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced today that it expects to recognize a one-time impairment charge of approximately RMB19.0 million (US$2.7 million) in the third quarter 2008 and affirmed its 2008 full year guidance.

Preliminary Third Quarter 2008 Selected Unaudited Financial Results

The Company's financial statements for the three months ended September 30, 2008 have not been finalized and are subject to completion of its normal quarter-end closing procedures. Therefore, the preliminary selected unaudited financial data set forth below may be subject to adjustment. As a consequence, actual results could differ materially from the expected results provided.

For the third quarter 2008, 3SBio expects total net revenues of approximately RMB68.2 million (US$10.0 million), representing an increase of 21.6% over the third quarter 2007. For the same period, 3SBio expects to recognize a one-time impairment loss of approximately RMB19.0 million (US$2.7 million). This impairment loss was related to a US$3.0 million aggregate principal amount of Floating Rate Credit Linked Notes due on January 21, 2009 (the "Notes") held by the Company. As a result, net income for the third quarter 2008 is expected to be approximately RMB1.9 million (US$0.3 million), or US$0.01 per ADS.

The Notes, issued by UBS AG, Jersey Branch (the "Issuer"), are linked to credit of Lehman Brot
'/>"/>

SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. 3SBio Inc. Announces Change to the Board of Directors
9. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. 3SBio Inc. Announces Promotion of David Chen as Chief Operating Officer
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... the National Institutes of Health (NIH), awarded a $2.18 million ... a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. ... ... UT (PRWEB) December 10, 2009 -- The National Eye Institute ... awarded a $2.18 million grant to Aciont Inc. to help ...
(Date:12/10/2009)... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today provided an update on the proposed ... Cytopia Ltd. into YM, details of which were ... directors of Cytopia has unanimously recommended that its ...
(Date:12/10/2009)... Vivakor, Inc. (OTC Bulletin Board: VIVK) today ... exclusive, $5 million license agreement with consumer ... ). The agreement exclusively licenses to ... nutraceutical formulation developed by Vivakor and provides ... Vivakor for Regeneca. Under the terms of ...
(Date:12/10/2009)... Martek Biosciences Corporation (NASDAQ: MATK) announced today that it ... global dairy company Fonterra Co-operative Group Limited for the use ... Materna products for pregnant and nursing mothers. , ... ... Martek Biosciences Corporation (NASDAQ: MATK) announced today that ...
Breaking Biology Technology:NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3
... ... Final Approval, PRINCETON, N.J., June 25 ... tentative approval,from the U.S. Food and Drug Administration to manufacture and ... Tablets were $239 million (IMS - MAT: March 2008)., Ranbaxy ...
... and Decreased Expenses, CARY, N.C., June ... helping academic, healthcare and research-centric organizations realize,the ... BioMarin,Pharmaceutical Inc., a leading biopharmaceutical research and ... to streamline and,enhance procurement functions for its ...
... TraumaCure Inc. – makers of the ground-breaking hemostatic agent, WoundStat™ – ... 13485 certification for its quality system for design, development, production and ... WoundStat in August 2007 , ... BETHESDA, Md. ...
Other Biology Technology:Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets 2SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement 2 TraumaCure Receives Prestigious ISO 13485 Certification 2
(Date:12/11/2009)... granted an 18-month, exclusive option to startup Thermalin ... The company must reach certain milestones in order ... license on therapies designed to help patients with ... that it hopes will become an important part ... Insulin is a therapeutic protein used to manage ...
(Date:12/11/2009)... , Montreal, December 11, 2009 Canadian ... cancer. In the December 11 edition of the prestigious ... de Montral and the Universit de Sherbrooke explain how ... activity of cytokines, hormones that are culprits in cancer-prone ... people exposed to asbestos. , "Excessive cytokine activity ...
(Date:12/11/2009)... editor of the 4th edition of Springer,s classic reference ... given the Victor A. McKusick Leadership Award. The prize, ... of human genetics, was presented to him at the ... Genetics on 24 October 2009 in Honolulu, Hawaii. , ... at the University of Washington in Seattle. One of ...
Breaking Biology News(10 mins):Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Scientists identify natural anti-cancer defenses 2Raptor Pharmaceutical Expands Board of Directors 5126 1Raptor Pharmaceutical Expands Board of Directors 5126 2Raptor Pharmaceutical Expands Board of Directors 5126 3Raptor Pharmaceutical Expands Board of Directors 5126 4Raptor Pharmaceutical Expands Board of Directors 5126 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 1Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 2Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 4Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 6Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 7Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 8Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 9MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 58629 1MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 58629 2MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 58629 3
... sulfate supplementation before preterm delivery cuts the risk for ... by University of Alabama at Birmingham (UAB) obstetrician Dwight ... of The New England Journal of Medicine. , ... affecting control of movement and posture and limiting activity. ...
... management agencies are proud to announce the First Southern ... the Visalia Convention Center, from 9:00 a.m. - 5:30 ... of Change Affecting the Southern Sierra Ecosystems." This ... be an outstanding educational and networking opportunity., The science ...
... will receive a special discretionary prize, as part of ... Sciences. The European Molecular Biology Organization (EMBO) awards the ... outstanding communication with the public. The additional award was ... on a single organism using all available media. ...
Other Biology News:Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 2Common treatment to delay labor decreases preterm infants' risk for cerebral palsy 3Southern Sierra Science Symposium planned for Visalia 2Southern Sierra Science Symposium planned for Visalia 3Southern Sierra Science Symposium planned for Visalia 4Southern Sierra Science Symposium planned for Visalia 5Southern Sierra Science Symposium planned for Visalia 6Southern Sierra Science Symposium planned for Visalia 7Southern Sierra Science Symposium planned for Visalia 8EMBO recognizes German zoologist for public communication 2
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: D H 100 ...
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
...
... 5-OxoETE-d7 is used as an internal standard ... isotope dilution mass spectrometry. 5-OxoETE is a ... of 5-HETE in human neutrophils. It stimulates ... EC50 of 2 nM. 5-OxoETE selectively stimulates ...
Biology Products: